SCHEMBL17695989

SCHEMBL17695989

CCCN(C)C(=O)c1ccc(NS)cc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 8/20 0.54
▸ ACACB O00763 1/20 0.46
▸ MCHR1 Q99705 1/20 0.43
▸ HDAC6 Q9UBN7 6/20 0.43
▸ EGFR P00533 1/20 0.42
▸ ERBB2 P04626 1/20 0.42
▸ PDK2 Q15119 1/20 0.41
▸ MLYCD O95822 1/20 0.41
▸ HDAC3 O15379 1/20 0.40
▸ HDAC4 P56524 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC7 Q8WUI4 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40
▸ HDAC10 Q969S8 1/20 0.40
▸ HDAC11 Q96DB2 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40
▸ HDAC9 Q9UKV0 1/20 0.40
▸ HDAC5 Q9UQL6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17696039 0.85 NAMPT (0.56) NAMPTACACBMCHR1HDAC6EGFR
SCHEMBL21077963 0.79 CDK4 (0.50) NAMPTACACBEGFRERBB2PDK2
SCHEMBL4495603 0.79 ESRRG (0.56) NAMPTACACBEGFRERBB2PDK2
SCHEMBL13123445 0.78 ALDH1A1 (0.53) —
SCHEMBL14640651 0.78 NAMPT (0.49) NAMPTACACB
SCHEMBL15218736 0.77 MCHR1 (0.56) NAMPTACACBMCHR1HDAC6EGFR
SCHEMBL5123550 0.77 NAMPT (0.48) NAMPTACACBEGFRERBB2PDK2
SCHEMBL12309792 0.77 ACACB (0.52) NAMPTACACBMCHR1HDAC6EGFR
SCHEMBL17914174 0.77 CDK4 (0.51) NAMPTACACBHDAC6EGFRERBB2
SCHEMBL1006489 0.77 NAMPT (0.54) NAMPTHDAC6PDK2MLYCDHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160106742-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY AGIOS PHARMACEUTICALS, INC. 2016-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160106742-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY PCK1, PDK3, PDK2 NAMPT 333/4885ACACB 267/4885MCHR1 4616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback